Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...

Nearly one in four adults in Louisiana are considered obese, so it may not come as a surprise that our state also leads the ...

Moving ahead, Rob Rowe, Regional Research Director and Head of Global Strategy at a large US bank is ‘ tactically bullish ’ on the back of continuing tech recovery and the markets “pricing in a soft ...

Eli Lilly and Company has shown rapid growth with significant revenue increases. Click here to find out why I've decided to ...

The U.K. government issued a new warning aimed at the misuse of GLP-1 therapies by those who don’t qualify for the meds but are instead using them for quick-fix weight loss.

Though Lilly has been in the spotlight for the success of its GLP-1 drugs, the pharma giant has also been investing in a ...

As obesity rates in the United States soar, insurance companies, including Medicaid and Medicare, are facing financial headwinds to pay for prescription drugs for weight loss. Semaglutide, the generic ...

Eli Lilly (LLY) is reportedly preparing to launch Mounjaro in Denmark, the home country of its leading rival in the ...

Weight-loss jabs are not a quick fix for an “Instagram body”, the Health Secretary has warned. The medicines regulator has ...

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...

Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...